descriptionsPioglitazone is a drug that reduces the amount of glucose sugar in the blood. It is in a class of anti-diabetic drugs called thiazolidinediones that are used in the treatment of type II diabetes. The other member in this class is rosiglitazone Avandia. Another member of this class troglitazone or Rezulin was removed from the market because of liver toxicity. Patients with type II diabetes cannot make enough insulin and the cells of their body do not respond normally to the reduced amounts of insulin that are present. Insulin is the hormone produced by the pancreas that stimulates cells to remove glucose from the blood. Pioglitazone often is referred to as an insulin sensitizer because it attaches to the insulin receptors on cells throughout the body and causes the cells to become more sensitive more responsive to insulin. As a result more glucose is removed from the blood. At least some insulin must be produced by the pancreas in order for pioglitazone to work.
Pioglitazone also lowers the level of glucose in the blood by reducing the production and secretion of glucose into the blood by the liver. In addition pioglitazone may alter the blood concentrations of lipids fats in the blood. Specifically it decreases triglycerides and increases the good HDL cholesterol. Pioglitazone received FDA approval on July 16 1999.
|